METHODS FOR IDENTIFYING RISK OF MELANOMA AND TREATMENTS THEREOF

Provided herein are methods for identifying risk of melanoma in a subject and/or subjects at risk of melanoma, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating melanoma, therapeutic methods for treating melanoma in a subject and compositions...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	KAMMERER, STEFAN, M, ROTH, RICHARD, B, NELSON, MATTHEW, ROBERTS, HOYAL-WRIGHTSON, CAROLYN, R, BRAUN, ANDREAS
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES DERIVATIVES THEREOF ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING NUCLEIC ACIDS NUCLEOSIDES NUCLEOTIDES ORGANIC CHEMISTRY PROCESSES OF PREPARING SUCH COMPOSITIONS SPIRITS SUGARS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Provided herein are methods for identifying risk of melanoma in a subject and/or subjects at risk of melanoma, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating melanoma, therapeutic methods for treating melanoma in a subject and compositions comprising one or more melanoma cells and one or more NRP1, NID2, ENDO180, CDK10, FPGT, CARD PCLO or REPS2 directed agents. These embodiments are based upon an analysis of polymorphic variations in a NRPI, NID2, ENDO180, CDK10, FPGT, CARK, PCLO or REPS2 nucleic acid, exemplified by nucleotide sequences of SEQ ID NO: 1-17. L'invention concerne des méthodes d'identification du risque de mélanome chez un et/ou des sujet(s) présentant un risque de mélanome. L'invention concerne également : des réactifs ; des kits destinés à mettre en oeuvre lesdites méthodes ; des méthodes d'identification de traitements candidats destinés à traiter le mélanome ; des méthodes de traitement du mélanome chez un sujet ; des compositions contenant au moins une cellule mélanique et au moins un agent dirigé sur NRP1, NID2, ENDO180, CDK10, FPGT, CARK, PCLO ou REPS2. Les modes de réalisation de la présente invention se fondent sur l'analyse des variations polymorphes observées dans un acide nucléique NRPI, NID2, ENDO180, CDK10, FPGT, CARK, PCLO OU REPS2, par exemple des séquences nucléotidiques de SEQ ID NO: 1-17.